New data associating NBTXR3 with preoperative chemotherapy indicate that NBTXR3 may fit into the treatment of head and neck cancer and other solid tumors – 06/05/2022 at 15:00


Data presented at the 2022 American Society for Clinical Oncology Annual Meeting
• NBTXR3 is being developed in order to be able to be integrated into therapeutic management in oncology: the data from phase 1b/2 studies in combination with chemotherapy, carried out within the framework of collaborations fall within this objective.
• In 12 evaluable patients with locally advanced stage IV head and neck cancer, data from a phase 1b/2 study showed that the combination of NBTXR3 with concurrent chemotherapy was feasible, had a favorable safety profile, a disease control rate of 100% and an overall response rate of 58.3%.
• In 31 evaluable patients with unresectable rectal cancer, data from a phase 1b/2 study showed that the combination of NBTXR3 with concomitant chemotherapy preoperatively was feasible, had a favorable safety profile and allowed 96% of patients to have complete surgical excision (R0) with, among the 25 patients operated on, a complete pathological response rate of 20%. The disease control rate was 100% and the overall response rate was 35.5%.



Source link -86